insitro is a drug discovery company that applies machine learning to large-scale human and cellular data in order to identify causal disease drivers and design therapeutics. Its work concentrates on neuroscience and metabolic diseases, areas where it maintains a broad pipeline of therapeutic candidates. The company's stated premise is that the prevailing drug discovery model is failing: more than 90% of drug candidates fail in clinical trials, despite billions of dollars and decades of effort expended across the industry.
At the centre of the company's approach is Virtual Human™, a genetically anchored causal AI engine built on what the company describes as the world's largest integrated multi-modal corpus of human and cellular data. The system is designed to reveal how disease begins, progresses and can be resolved. Complementing it is TherML™, an AI platform used to design optimal medicines once the causal genetic drivers of a disease have been identified. Together the two form an industrialised, self-learning architecture: each new biology onboarded is intended to improve the predictive performance of the models.
Technical work at insitro spans causal AI, machine learning, multi-modal biological data generation, human genetics, cellular data and therapeutic design. The day-to-day emphasis is on identifying important questions, designing and scaling experiments, building models and analysing results. Teams are interdisciplinary by design, with life scientists, data scientists, engineers and drug hunters working together, and the company states a mission of bringing better drugs faster to patients who can benefit most.
